2seventy bio, Inc. (NASDAQ:TSVT) Given Average Rating of “Moderate Buy” by Brokerages

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $9.00.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 2seventy bio in a research report on Saturday.

2seventy bio Trading Up 7.0 %

Shares of NASDAQ:TSVT traded up $0.17 during trading on Friday, hitting $2.61. 380,020 shares of the stock were exchanged, compared to its average volume of 398,038. The company has a market cap of $134.65 million, a PE ratio of -1.40 and a beta of 1.76. The company has a fifty day moving average price of $3.28 and a two-hundred day moving average price of $4.15. 2seventy bio has a 12-month low of $2.35 and a 12-month high of $6.40.

Institutional Trading of 2seventy bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its stake in shares of 2seventy bio by 1.1% during the third quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after buying an additional 13,144 shares during the period. XTX Topco Ltd raised its holdings in 2seventy bio by 61.1% in the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after acquiring an additional 9,257 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of 2seventy bio by 9.0% during the 3rd quarter. Wellington Management Group LLP now owns 262,040 shares of the company’s stock worth $1,237,000 after purchasing an additional 21,673 shares during the period. Western Standard LLC acquired a new stake in shares of 2seventy bio during the third quarter worth $1,350,000. Finally, State Street Corp grew its position in shares of 2seventy bio by 1.5% in the third quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after purchasing an additional 15,638 shares during the period. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.